About

Cortney Inman is an associate in the Governmental Practice Group in the firm's Washington, D.C. office and a member of the FDA Regulatory and Life…

Cortney Inman is an associate in the Governmental Practice Group in the firm's Washington, D.C. office and a member of the FDA Regulatory and Life Sciences teams.

Latest Post

On August 11, 2023, the Office of Prescription Drug Promotion (OPDP) of the U.S. Food and Drug Administration (FDA) issued an untitled letter to Exeltis USA Inc. (Exeltis) regarding a promotional social media sponsored post for SLYND® (drospirenone) oral progestin tablets, indicated for use by females of reproductive potential to prevent pregnancy (Slynd).[1] The post appeared on Facebook,[2] and, in addition to being false and misleading, also was not submitted to OPDP at the time of publication as required by FDA regulations. This is only the second untitled letter from OPDP of the year, both of which have focused on false and misleading promotional messaging.

Continue Reading FDA’s Office of Prescription Drug Promotion Issues Second Untitled Letter of the Year to Exeltis for Misleading Statements Relating to SLYND®

About

Cortney Inman is an associate in the Governmental Practice Group in the firm's Washington, D.C. office and a member of the FDA Regulatory and Life…

Cortney Inman is an associate in the Governmental Practice Group in the firm's Washington, D.C. office and a member of the FDA Regulatory and Life Sciences teams.

Subscribe: Subscribe via RSS